ArticleNature communications2026
Characterization of post-mitotic DNA synthesis and its regulation in human cells.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
DNA replication stress promotes cancer development and is associated with DNA synthesis beyond S-phase. Replication stress-induced DNA lesions and under-replicated DNA can persist into G2 and mitosis, where they undergo mitotic DNA synthesis (MiDAS). After cell division, inherited DNA lesions are protected by genome caretaker proteins and show signs of post-mitotic DNA synthesis (post-MiDAS) in G1. The genomic regions that undergo post-MiDAS, the cellular factors involved, and the implications for genome integrity remain poorly understood. Here, we provide evidence for post-MiDAS activity at centromeres and telomeres in cancer cells employing alternative lengthening of telomeres (ALT) and present data suggesting that a subset of these fragile genomic regions can cluster during post-MiDAS in G1. We further show that post-MiDAS is promoted by local SUMOylation and BLM recruitment into ALT-associated PML bodies (APBs) and involves DNA damage tolerance factors and proteins associated with ALT and MiDAS. Consistent with G1-specific regulation, complementary quantitative proteomics and targeted siRNA screening reveal that APC/C, together with its G1 co-activator CDH1 but independent of its mitotic co-activator CDC20, restrains excessive post-MiDAS in G1. Finally, we show that CDH1 depletion selectively impairs the survival of ALT-positive cancer cell lines, indicating that post-MiDAS might represent a potential ALT-specific vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.